Recent study shows, biomarkers help identify children
with cancer at risk for cognitive impairments. Explore more about cancer at: http://bit.ly/2K4sRl4
Showing posts with label oncology conferences 2019. Show all posts
Showing posts with label oncology conferences 2019. Show all posts
Monday, October 28, 2019
Saturday, October 5, 2019
Cancer Summit 2019
Trials show, circulating
tumor DNA detected through liquid biopsy, to be an independent prognostic
marker for identifying patients with colorectal cancer. Explore more oncology,
PS: https://cancer-oncology.pulsusconference.com/
Saturday, September 28, 2019
Cancer Summit 2019
Study shows that combination
of cediranib and olaparib proves effective and safe for women with heavily
pretreated, platinum-resistant ovarian cancer. To explore more oncology, PS:
Saturday, September 7, 2019
Breakthrough therapy designation to capmatinib- Lung Cancer
The FDA granted
breakthrough therapy designation to capmatinib for first-line treatment of
metastatic MET exon 14 skipping-mutated non-small cell lung cancer.
MET mutations — identified
in approximately 4% of patients with NSCLC — are associated with poor
prognosis. The mutations, typically seen among older patients, can limit
treatment options.
No targeted therapies are approved to treat
MET exon 14 skipping-mutated NSCLC, an aggressive subtype of the disease.
Prior studies have shown
capmatinib (INC280, Novartis) — an investigational, oral MET inhibitor — to be
highly selective and potent in this setting, according to a Novartis-issued
press release. The FDA previously granted breakthrough therapy designation to
the agent for treatment of patients with this type of NSCLC who received prior
platinum-based chemotherapy.
“We look forward to working
with the FDA and global health authorities to bring capmatinib to patients who
currently have no available targeted therapy options,” John Tsai, MD, head
of global drug development and chief medical officer of Novartis, said in the
release.
Tuesday, August 27, 2019
Recent Trends in Oncology
Study
shows that de-intensified chemoradiotherapy regimen shows favorable clinical
outcomes among for HPV-associated oropharyngeal squamous cell carcinoma. Learn
more about oncology at: http://bit.ly/2Yxiv66
Thursday, August 22, 2019
Recent Trends in Oncology
Research
shows that patients with metastatic colorectal cancer who exercised regularly
achieved longer PFS than those who did not. Learn more about oncology at: http://bit.ly/2Yxiv66
Wednesday, August 21, 2019
Recent Trends in Oncology
Research
reveals that combo of palbociclib & cetuximab shows antitumor activity for platinum
or cetuximab resistant HPV unrelated head and neck squamous cell carcinoma. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows that breast cancer screening at a younger age prevent more than half of
all breast cancer-related deaths among childhood cancer survivors treated with
chest radiation. Learn more about oncology at: http://bit.ly/2Yxiv66
Monday, August 19, 2019
Recent Trends in Oncology
FDA
has approved fedratinib for intermediate-2 or high-risk primary or secondary
myelofibrosis. Learn more about oncology at: http://bit.ly/2Yxiv66
Recent Trends in Oncology
Applying
biomolecular engineering and synthetic biology techniques to develop “smarter
and stronger” T cells provides more effective and less toxic cancer therapy. Explore
more about cancer at: http://bit.ly/2K4sRl4
Friday, August 16, 2019
Recent Trends in Oncology
A
new study found that eating flavonoid rich foods reduce the risk of cancer. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
FDA
granted approval to entrectinib for the treatment of adults and children with
cancers that harbor NTRK, gene fusion and for whom there are no effective
treatments. Learn more about oncology at: http://bit.ly/2Yxiv66
Wednesday, August 14, 2019
Recent Trends in Oncology
Study
suggests that replacing red meat with poultry lowers breast cancer risk. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows that abiraterone acetate and enzalutamide increase the risk for death
among old men with advanced prostate cancer and pre-existing cardiovascular
conditions. Know more about oncology at: http://bit.ly/2Yxiv66
Tuesday, August 13, 2019
Recent Trends in Oncology
Research
shows that cytoreductive surgery may be an effective treatment option for
specific subgroups of patients with primary central nervous system lymphoma. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows men with prostate cancer with +ve surgical margins, extracapsular
extension achieved longer biochemical RFS after radical prostatectomy with
adjuvant radiotherapy compared with only surgery. Know more Oncology at: http://bit.ly/2Yxiv66
Friday, August 9, 2019
Recent Trends in Oncology
Recent
report shows that adults aged over 85 years show unexpectedly high cancer
screening rates. Explore more about oncology at: http://bit.ly/2K4sRl4
#CancerConference
#OncologyConferences
Recent Trends in Oncology
New
research finds that cfDNA in blood helps in non-invasive diagnosis of cancer. Get
to know more about cancer at: http://bit.ly/2Yxiv66
#CancerConferences
#OncologyConference
Wednesday, August 7, 2019
Recent Trends in Oncology
New
CAR-T Therapy derived from iPSCs has been transferred for clinical testing. Get
to know more about cancer at: http://bit.ly/2K4sRl4
#CancerConferences #OncologyConference
Recent Trends in Oncology
EMA
recommend approval of pembrolizumab and axitinib combination for first line
treatment of advanced renal cell carcinoma. Explore more about oncology at: http://bit.ly/2K4sRl4
#CancerConference
#OncologyConferences
Subscribe to:
Posts (Atom)